<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00223509</url>
  </required_header>
  <id_info>
    <org_study_id>0340013418</org_study_id>
    <nct_id>NCT00223509</nct_id>
  </id_info>
  <brief_title>Lamictal As Add on Treatment in Mixed States of Bipolar Disorder</brief_title>
  <official_title>Lamictal As Add on Treatment in Mixed States of Bipolar Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  To evaluate the efficacy and safety of LAM+existing regimen of mood stabilizer in the
           acute treatment of patients in a mixed state of bipolar disorder.

        -  To evaluate the efficacy and of a combination of LAM+existing regimen of mood
           stabilizers in the maintenance treatment of patients with mixed state of bipolar
           disorder
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. To evaluate the efficacy and safety of LAM+existing regimen of mood stabilizer in the
           acute treatment of patients in a mixed state of bipolar disorder.

        2. To evaluate the efficacy and of a combination of LAM+existing regimen of mood
           stabilizers in the maintenance treatment of patients with mixed state of bipolar
           disorder
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary efficacy, during the first 10 weeks (acute phase) of the study, will be assessed by the proportion of patients achieving a 50% reduction of their depressive symptoms as assessed by the MADRS and a GAF</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>MADRS</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Efficacy, during the maintenance phase of the study, will be assessed by the proportion of patients able to maintain a response, at the end of the study, as defined by</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>MADRS total score of &lt;14, GAF score 51. Secondary measures will include the YMRS, and CGI Bipolar version.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary measures will include the YMRS, and CGI Bipolar version.</measure>
  </secondary_outcome>
  <enrollment type="Actual">28</enrollment>
  <condition>Bipolar Disorder</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lamotrigine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        In order to be included in the study patient must meet criteria A, C, D, E, F, G plus any 1
        of the 3 criteria listed in section B.

        A. Patients meeting DSM-IV diagnosis of bipolar disorder, I or II

        B.

          1. Patients meeting DSM-IV diagnostic criteria for a manic/hypomanic episode with the
             simultaneous presence of (or rapid alteration within minutes) of at least three DSM-IV
             depressive symptoms excluding psychomotor agitation or

          2. Patients meeting DSM-IV symptomatic criteria for a hypomanic/manic episode for a
             period of 2 days or longer, with the simultaneous presence of (or rapid alteration
             within minutes) of at least three DSM-IV depressive symptoms excluding psychomotor
             agitation or

          3. Patients meeting DSM-IV criteria for a depressive episode associated with at least
             three DSM-IV manic/hypomanic symptoms

        C.MADRS of ≥14

        D.YMRS of ≥ 14

        E. Age 13years to 75 years

        F. Male or female

        G. Outpatient

        Exclusion Criteria:

          1. illness precluding the use of LAM

          2. Alcohol/drug dependence in the past one month

          3. patients with a history of a rash on LAM

          4. CNS neoplasms, demyelinating diseases, degenerative neurological condition or active
             CNS infection

          5. history of seizure, known EEG with frank paroxysmal activity, known CT of brain
             showing gross structural abnormalities, cerebral vascular disease by history or
             structural brain damage from trauma

          6. patients currently taking LAM
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vivek - Singh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Charles L Bowden, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Univ of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>June 19, 2012</last_update_submitted>
  <last_update_submitted_qc>June 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mixed mania</keyword>
  <keyword>lamotrigine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamotrigine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

